Astrocytes Regulate the Health and Degeneration of Retinal Ganglion Cells in Glaucoma Neurodegeneration
About the Research Project
Program
Award Type
Standard
Award Amount
$180,000
Active Dates
September 01, 2020 - August 31, 2022
Grant ID
G2020369
Goals
Astrocytes are known to play vital roles in the maintenance of retinal ganglion cells, with these interactions adversely affected in glaucoma. In particular, as is common across a number of neurodegenerative diseases, the mitochondria of these cells are damaged, presumably leading to the disease phenotypes. The use of human pluripotent stem cells allows for the precise modeling of these interactions in a dish, providing the spatial and temporal resolution to closely examine how mitochondrial function is changed in these cells as a result of glaucoma, as well as how these changes in mitochondria alter the health and function of the cells as a whole.
Summary
The goal of this project is to examine the ways in which astrocytes, a type of support cell found throughout the central nervous system, can be adversely affected in glaucoma, leading to the degeneration of retinal ganglion cells. To accomplish this, we will utilize an in vitro human pluripotent stem cell model of glaucoma derived from samples from patients with inherited forms of the disease, as well as unaffected control cell lines. These cells will be differentiated into both retinal ganglion cells and astrocytes, and these differentiated cells will be grown together to examine the ways in which astrocytes regulate retinal ganglion cell function and viability. Through the use of these stem cell models, we are able to analyze mechanisms underlying the disease state in astrocytes and retinal ganglion cells in a human cellular model. Once the study is complete, we hope that results will illustrate the importance of astrocytes in the disease state, providing new pathways for the development of therapeutic approaches to glaucoma.
Related Grants
National Glaucoma Research
The Immune Landscape of the Human Optic Nerve Head
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Monica Vetter, PhD
Current Organization
University of Utah
The Immune Landscape of the Human Optic Nerve Head
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Monica Vetter, PhD
Current Organization
University of Utah
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
News Featuring This Grantee
National Glaucoma Research Grantee Receives $2.2 Million Follow-On Award Aimed at Curing Blindness
Additional funding is propelling BrightFocus-funded scientist Jason Meyer, PhD, toward advances in whole-eye transplantation.